Neurotransmitterreceptors that increase phosphatidylinositol hydrolysis generate second messengers that activate protein kinase C. Here, we used metabotropic glutamate receptor agonists to increase both phosphatidylinositol hydrolysis and secretion of the soluble extracellular fragment of amyloid precursor protein (APPs) from cortical astrocyte cultures. The increase in APPs secretion was mimicked by direct activation of protein kinase C with phorbol ester and was suppressed by the metabotropic glutamate receptor antagonist L-(+)-2-amino-3-phosphonopropionic acid or by the protein kinase C inhibitor GF109203X. lonotropic glutamate agofists did not increase APPs secretion. Forskolin or dibutyryl cyclic AMP inhibited the increase in APPs secretion caused by metabotropic glutamate receptor agonists or by phorbol ester treatment but did not affect basal APPs levels. Therefore, glutamatergic agonists that increase protein kinase C activation or decrease cyclic AMP formation may enhance the conversion of full-length APP to nonamyloidogenic APPs in Alzheimer's disease.
Senile plaques found in Alzheimer' s disease (AD) are principally composed of abnormal aggregates of amyloid peptides (A/3s), which are released by proteolytic cleavage of a much larger transmembrane protein, the amyloid precursor protein (APP). The first 28 amino acid residues of A/3, like the large N-terminus of APP, extend into the extracellular space. The remaining 12-15 residues of A/3 are anchored within the cell membrane and are attached to the short, cytoplasmic C-terminus of APP (Selkoe, 1994) . Constitutive APP processing creates a cleavage within the A/3 peptide to prevent amyloid formation; the soluble extracellular fragment of APP (APPs) is then secreted into the extracellular medium. APP overexpression or missense mutations may increase A~3formation by a!-tering constitutive APP processing pathways (Checler, 1995) . Because reinternalization of APP retaining the intact A~~3 domain may increase A/3 production, strategies directed at increasing APP processing or APPs secretion have been proposed to prevent amyloid plaques in AD.
Neurotransmitter agonists coupled to phosphatidylinositol (PT) hydrolysis can increase APPs secretion and decrease A/3 formation (Buxbaum et al., 1992; Nitsch et a!., 1992; Lee et al., 1995a; Wolf et al., 1995) . This form of nonamyloidogenic processing is mediated in large part by the second messengers derived from PT hydrolysis, diacylglycerol and inositol trisphosphate, which activate protein kinase C (PKC).
Astrocytes express abundant levels of APP but, unlike neurons and most cell lines, undergo low levels of constitutive processing and secrete relatively small quantities of APPs (Haass et al., 1991) . Moreover, astrocytes, unlike neurons, reportedly do not increase APPs secretion in response to direct activation of PKC . Instead, astrocytes secrete abundant levels of A/3s . Thus, astrocytes found in proximity to senile plaques and degenerating neurites may be a significant nonneuronal source of A/3.
Astrocytes express various neurotransmitter receptors that are coupled to ion channels or second messengers. We explored the possibility that metabotropic glutamate receptor (mGluR) agonists, which activate the PI/PKC cascade, may stimulate APPs secretion in astrocyte cultures. Because mGluR can potentiate cy-clic AMP (cAMP) formation (Schoepp and Conn, 1993) , we also examined the effect of cAMP signaling on APPs secretion. Parts of this work have been presented in abstract form (Lee et al., 1995b) .
EXPERIMENTAL PROCEDURES

Cortical astrocyte cultures
Neonatal rat pups (1-3 days old) were overdosed with ketamine hydrochloride (Sigma) before decapitation. Astrocytes were obtained from dissected cortices using protocols described by McCarthy and de Vellis (1980) . In brief, cortices were incubated in Hanks' buffered saline solution (GIBCO) containing 0.5% trypsin/0. 1% deoxyribonuclease I (both from Sigma) for 30 mm at 37°C.The cell pellet coblected after centrifugation was resuspended in minimum essential medium (GIBCO) containing 10% horse serum and plated onto poly-L-lysine-coated 35-mm-diameter culture dishes (.-~i0 5 cells/cm2). Cells were kept at 37°Cin a humidified 5% C0 2/air incubator. Confluent astrocytes were used for experiments. Immunocytochemical staining with an antibody for glial fibrillary acidic protein (Boehringer Mannheim) labeled >95% of the cultured cells.
Pharmacological treatments
The following drugs were dissolved in water, ethanol, or dimethyl sulfoxide and diluted to working concentrations from frozen stock solutions (10_2_10_4 M): GF109203X from LC Laboratory; phorbol 12-myristate 13-acetate 
APPs level measurements
Astrocytes were exposed for 1 h to 1.5 ml of serum-free media containing the drug(s) to be tested. Secreted APPs was quantified using protocols similar to those described by Lee et a!. (1995a) . In brief, a cocktail of protease inhibitors (Nitsch et al., 1992) was added to the media, which were then desalted in columns containing Sephadex G25 beads (Bio-Rad) and lyophilized in a rotary evaporator. Cells remaining in the dishes were rinsed (3 x 1 ml) and scraped into 1 ml of ice-cold phosphate-buffered saline for measurements of protein concentration using the bicinchoninic acid assay. Lyophilized media were dissolved in 20~.t1 of extraction buffer (50 mM Tris buffer, 5 mM EDTA, and 150 mM NaC1, pH 7.6) containing 2% Nonidet P.40 and 2% Triton X-lOO and diluted with 20~zlof loading buffer (125 mM Tris buffer, 4% sodium dodecyl sulfate, 20% glycerol, 5% 2-mercaptoethanol, and 0.01% bromphenol blue, pH 6.8).
Samples were boiled (5 mm) before electrophoresis. The amount of protein loaded on 12% sodium dodecyl sulfate polyacrylamide gels for each sample was corrected for the total amount of cell protein per dish. The proteins were electroblotted onto polyvinylidene difluoride membranes (Millipore), which were subsequently incubated overnight in monoclonal antibody 22C1 1 or Alz-90 (from Boehringer Mannheim) or the polyclonal antiserum R1285 (a gift from Dr. D. J. Selkoe, Harvard Medical School) . Antibody 22C1 1 and Alz-90 and antiserum R1285 are directed against N-terminus residues 60-100 (Weidemann et al., 1989), 5 11-608 (Boehringer Mannheim), and 527-540 (Haass et al., 199!) of APP, respectively (numbering according to APP695).
Immunolabeling was visualized by a secondary antibody conjugated to horseradish peroxidase (Amersham). Enhanced chemiluminescence (Du Pont NEN) was used to detect antibody immunoreactivity, and the transfer blots were exposed to Kodak X-Omat film. Labeled APP proteins were quantified by laser scanning densitometry (LKB, Sweden). When immunoreactive bands appeared as doublets on western blots, the densitometry signals from both bands were summed.
P1 hydrolysis assay
Inositol phospholipids were quantified using protocols similar to those described by Lee et al. (!995a) . In brief, confluent astrocyte cultures were incubated for 24 h with serum-free minimum essential medium containing 2~Ci of myo-[2-3H]inositol (Du Pont NEN; 1 Ci = 37 GBq). The cells were rinsed in serum-free minimum essential medium containing 10 mM LiC1 before pharmacological treatments, which lasted 1 h. The cells were scraped into 1 ml of chloroform and 0.5 ml of water. After vortex-mixing the solution, the aqueous and organic phases were separated by centrifugation. One milliliter of the aqueous phase was loaded onto columns containing AG1-X8 anion-exchange resin (BioRad) for separation of [3HI inositol-containing compounds.
Free [3H]inositol was eluted into scintillation vials with 4 ml of 1 M ammonium formate/0. 1 M formic acid. P1 hydrolysis was estimated from the amount of radioactivity measured on a Beckman model LS7500 liquid scintillation counter.
Data analysis
Measurements of APPs levels and P1 hydrolysis in different treatment groups were standardized against those of control groups. Differences between groups were evaluated by Student's t tests and ANOVA (p < 0.05).
RESULTS
Effects of mGluR agonists and antagonists on APPs secretion and P1 hydrolysis
Treatment of astrocytes with L-Glu, QA, or ACPD (10 /2M-1 mM) caused highly significant and concentration-dependent increases in P1 hydrolysis (p <0.05). The relative order of potency of these mGluR agonists was QA > L-Glu > ACPD (Fig. 1) . At 1 mM, the highest concentration tested, QA, L-Glu, and ACPD increased P1 hydrolysis by 650, 530, and 480%, respectively.
The amount of secreted APPs, detected as a '-~!00-kDa protein band in the media using monoc!onal antibody 22C11 or Alz-90 or antiserum R1285, was increased by the mGluR agonist ACPD (Fig. 2) . L-Glu, ACPD, and QA significantly increased APPs levels by 1.5-fold relative to baseline levels (p <0.05). Simi-!ar increases in APPs levels by ACPD stimulation were detected by antibody 22C1 1 or Alz-90 or antiserum R1285. The increase in content of APPs stimulated by mGluR agonists was not concentration-dependent in the range examined, i.e., 10 p~M-1mM. Also, 1
Effect of mGluR agonists on P1 hydrolysis in confluent astrocytes. Triplicate dishes of astrocytes were treated with various concentrations of the mGluR agonist L-Glu, QA, or ACPD for 1 h, in serum-free medium containing 10 mM lithium. P1 hydrolysis was estimated from the accumulation of radiolabeled inositol phosphates in the aqueous phase of cell extracts. Data are mean ± SEM (bars) values from four independent experiments (p < 0.05).
concentrations of mGluR agonists failed to increase APPs secretion or PT hydrolysis. Tn confirmation of previous findings on hippocampal neurons (Lee et al., 1995a) , activation of ionotropic glutamate receptors with S(-)-5-fluorowillardiine or NMDA failed to affect P1 hydrolysis or APPs secretion.
Exposing astrocytes to the mGluR antagonist MCPG (500 ,uM) blocked the threefold increase in PT hydrolysis caused by 100 1uM ACPD (p < 0.05) but not the stimulation of APP processing; APPs levels in the medium were increased in the presence of ACPD, with or without MCPG (Fig. 3) . Another mGluR antagonist, L-AP3 (100~.tM), had no significant effect on basal or stimulated PT hydrolysis but did completely suppress the stimulation of APPs secretion by 100 4uM L-Glu, QA, or ACPD ( Fig. 4 ; p <0.05).
Effect of PKC and cAMP on APPs secretion
PMA (5 suM) mimicked the stimulatory effects of mGluR agonists, increasing APPs secretion by 1.7-fold relative to that by untreated control cells (p <0.05) . The PKC inhibitor GF109203X inhibited the APPs secretion elicited by mGluR agonists or PMA (Fig. 5) .
APPs secretion in response to mGluR agonists or to PKC activation by PMA (5 ,uM) was potently inhibited (p < 0.05) by exposing astrocytes to the membranepermeant dBcAMP or to forskolin (both 100~tM). Although forskolin or dBcAMP occasionally did suppress basal APPs secretion, this inhibitory effect was not consistent in the absence of mGluR agonists or PMA (Fig. 6 ). The enhancement of PT hydrolysis by ACPD (100~.iM) was partially but significantly suppressed by dBcAMP (100 1uM) treatment, i.e., by '-'20%; however, the production of 3H-inositol phosphates remained significantly above baseline (p <0.05).
DISCUSSION
These data show that exposure of short-term astrocyte cultures to the metabotropic glutamate agonist L-Glu, QA, or ACPD promotes nonamyloidogenic APP processing and increases APPs secretion. L-Glu, QA, and ACPD also stimulated PT hydrolysis, sug- Fig. 1 was measured in culture dishes containing ACPD (100 jiM) with or without L-AP3 (100 jiM) or neither drug (°p < 0.05). Data are mean ± SEM (bars) values. B: APP5 secretion in culture dishes containing LGlu, QA, or ACPD (all 100 jiM) with or without the putative mGluR antagonist L-AP3 (100 jiM). APPs was detected on western blots using antibody 22C1 1. lation of APP processing by mGluRs but not ionotropic receptors in astrocytes is consistent with our previous observation that ion channels on neurons do not regulate APP processing (Lee et al., 1995a) . Hence, increases in APPs secretion produced by the nonspecific glutamate agonists L-Glu and QA are probably not mediated by their actions on ionotropic glutamate receptors.
The nonselective antibody 22C 11, which was used to quantify astrocytic APPs, also recognizes a highly homologous polypeptide, APLP2 (Slunt et al., 1994) . We confirmed that the peptide secreted during stimulation by mGluR agonists was indeed APPs by using an antibody, Alz-90, and a polyclonal antiserum, R1285, that are directed at epitopes specific to the extracellular domain of APP (Haass et al., 1991; Storey et al., 1996) . Tmmunoblotting with these three antibodies   FIG. 5 . Effect of PKC inhibition on the increase in APP5 secretion caused by mGluR agonists or phorbol ester. APPs secretion from astrocytes prepared as in Fig. 1 was assayed by immunoblotting with antibody 22C1 1. Culture dishes contained the mGluR agonist L-GIu, QA, or ACPD (all 100 jiM) or PMA (5 jiM), with or without the PKC inhibitor GF109203X (2.5 jiM). PKC inhibition blocked the increase in APPs secretion caused by the mGluR agonists or PMA. Note that truncated APPs had faster mobility, i.e., lower molecularweight, than fulllength APP (*) obtained from rat brain.
confirmed that mGluR activation increased APPs secretion.
The stimulatory effects of mGluR agonists on astrocytic APPs were suppressed by the PKC inhibitor GF109203X (Toullec et al., 1991) and mimicked by phorbol ester, suggesting that promotion of APP processing by mGluR agonists can involve PT/PKC signaling. Our data contradict the previous report that human astrocytes and glioma cells do not respond to PKC activation by increasing APPs secretion and suggest that the regulation of APP processing by phorbol ester may be specific for certain cell types. We previously showed that APPs secretion stimulated by PKC is associated with a decrease in the levels of cell-associated APP holoprotein and is not dependent on APP synthesis (Slack et al., 1993) . Moreover, neurotransmitters typically increase APPs secretion from cells within 5-15 mm of stimulation (Nitsch et al., 1992) , suggesting that de novo APP synthesis is not required for increased APPs secretion.
None of our drug treatments increased the levels of cell-associated APP in cultured astrocytes (authors' unpublished data). Because neurotransmitters coupled to cAMP but not to PKC activation stimulated APP synthesis in astrocytes (Lee et al., 1996) , we suggest that the increase in APPs secretion following mGluR or phorbol ester treatment observed in our study results from proteolytic processing of preexisting APP and not from increased APP synthesis.
Although neurotransmitter agonists can stimulate the secretion of soluble and truncated forms of APP, e.g., APPs, cholinergic stimulation of primary bovine chromaffin cells resulted in the secretion of APP holoprotein ('--.'130 kDa) (Efthimiopoulos et al., 1996b ).
In our study on astrocytes, the APP whose release is induced by mGluR agonists is probably a truncated APP fragment, i.e., APPs, and not full-length APP. On western blots, antibody 22C 11 or Alz-90 and antiserum R1285 detected a protein band of '-~100 kDa from the media that had faster mobility than full-length APP ('--130 kDa) obtained from rat brain homogenates. Astrocytes express the larger APP transcripts, such as APP75 1 and APP77O, in addition to the smaller APP695 isoform that is expressed by brain neurons (Haass et al., 1991) . Therefore, APP holoprotein in the media of astrocytes might be expected to have slower mobility on western blots compared with APP .1. Neurochem., Vol. 68, No. 5, 1997 FIG. 6. Effect of dBcAMP or forskolin on APPs secretion caused by mGluR agonists or PMA. A: Cultured astrocytes prepared as in Fig. 1 were exposed to the mGluR agonist L-Glu, QA, or ACPD (all 100 jiM), with or without dBcAMP and forskolin (both 100 jiM). All three mGluR agonists significantly increased APP secretion as measured by western blots using antibody 22C1 1 (*p <0.05), and this increase was blocked by dBcAMP or forskolin (both 100 jiM). Data are mean ±SEM (bars) values accumulated from four independent experiments. B: Representative western blot of APP secretion in cells exposed to PMA or ACPD, with or without dBcAMP, or neither drug.
holoprotein from rat brains, However, this was not the case. APP secreted by astrocytes had faster mobility than APP holoprotein from rat brain, suggesting that PMA or mGluR agonists stimulated the release of C-terminal truncated forms of APP, i.e., APPs. Antibodies directed against the C-terminus of APP did occasionally detect low levels of APP in the media, suggesting that both APP holoprotein and APPs are released by cultured astrocytes (authors' unpublished data). However, the levels of APP bearing intact Cterminal fragments did not appear to be significantly altered by drug treatments, suggesting that mGluR or PKC activation did not increase the secretion of APP holoprotein. Thus, the increase in APP levels observed with mGluR or PKC activation most likely results from accelerated constitutive APP processing and increased APPs secretion.
L-Glu, QA, and ACPD act on various mGluR subtypes to generate various second messengers (Nakanishi, 1992) . Glutamate-stimulated APP processing in astrocytes must involve other signal transduction systems independent of the PI/PKC signaling cascade, inasmuch as MCPG inhibited the increase in PT content caused by mGluR activation without suppressing the increase in APPs secretion. Also, the putative mGluR antagonist L-AP3 effectively inhibited the stimulation by mGluR agonists of APPs secretion but not of PT hydrolysis, indicating that P1 hydrolysis and APPs secretion are not necessarily coupled in astrocytes. The dissociations between APPs secretion and PT hydrolysis suggest that the mGluR antagonists we have used may not be specific for the particular mGluRs that are coupled to PT hydrolysis (Manev et al., 1993) . Alternatively, L-Glu, QA, and ACPD may be generating intracellular signals, e.g., phospholipase A 2, independent of the PT/PKC cascade, to increase APPs secretion (Emmerling et al., 1993 ).
An increase in number of /32-adrenergic receptors coupled to cAMP formation has been detected in the postmortem AD brain (Kalaria et al., 1989) . The effects of cAMP signaling on APP processing or synthesis are not known. Recently, Efthimiopoulos et al. (1996a) reported that elevations in intracellular cAMP level inhibit constitutive and phorbol ester-stimulated APPs secretion from C6 cells transfected with APP751. In contrast, Xu et al. (1996) showed that forskolin or activation of protein kinase A mimicked the action of phorbol esters, increasing APPs secretion from PCI2 cells. The discrepant effect of cAMP signaling on constitutive APPs secretion has not been resolved.
In our study, dBcAMP or forskolin inhibited the increase in APPs secretion caused by mGluR agonists or phorbol ester. In both C6 cells (Efthimiopoulos et al., l996a) and cortical astrocytes (Lee et a!., 1996) , the stimulation of cAMP production by the~3-adrenergic agonist isoproterenol also opposed the stimulatory effect of phorbol ester, indicating that activation of receptors that elevate the intracellular cAMP level inhibits APPs secretion. The inhibitory effects of forskolin or dBcAMP on APPs secretion is not related to nonspecific toxicity, as neither drug had a significant effect on basal APPs levels. Furthermore, prolonged treatment ( '--24 h) of cortical astrocytes with dBcAMP or forskolin did not cause cell death but actually promoted the synthesis of APP mRNA and protein (Lee et al., 1996) . Because PMA stimulation of APPs secretion was suppressed by dBcAMP or forskolin, cAMP signaling may act downstream of the PI/PKC cascade to inhibit APP processing. However, elevations in intracellular cAMP concentrations may also interfere with the formation of such second messengers as diacylglycerol and inositol trisphosphate, because dBcAMP partially suppressed the P1 hydrolysis caused by ACPD treatment. Astrocytes are a significant source of amyloid and can contribute to the neuropathology by up-regulating APP expression during neuronal injury (Siman et al., 1989) . In addition to mUluR agonists, which increase APPs secretion, serotoninergic agonists, e.g., dexnorfenfiuramine, a metabolite of the antiobesity drug dexfenfiuramine, can also stimulate P1 hydrolysis and APPs secretion in astrocyte cultures (authors' unpublished data) as has also been shown in 3T3 fibroblasts expressing 5-HT2a or 5HT2c receptors (Nitsch et al., 1996) . Thus, activation of various cell surface recep-.J. Neurochem., Vol. 68, No. 5, 1997 tors on astrocytes can be used to promote nonamyloidogenic processing of APP.
In summary, the present study shows that enhancing glutamatergic transmission in astrocytes can accelerate APP processing to form APPs. Inasmuch as the neurodegeneration and synapse loss of AD may be associated with an up-regulation of astrocytic APP (Siman et al., 1989) and with decreased glutamate levels (Francis et al., 1993) , glutamatergic agonists that increase PKC activation or inhibit cAMP formation may have therapeutic usefulness in AD by promoting nonamyloidogenic APP processing and improving synaptic transmission.
